Trial Profile
Comparative Randomized, Single Dose, Three Way Three Sequence Two Treatment Partial Replicate Crossover Study to Determine the Bioequivalence of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2021
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Aicardi-Goutieres syndrome; Alopecia areata; Atopic dermatitis; COVID 2019 infections; Diabetic nephropathies; Hereditary autoinflammatory diseases; Juvenile rheumatoid arthritis; Myositis; Polymyalgia rheumatica; Primary biliary cirrhosis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Uveitis
- Focus Pharmacokinetics
- 23 Aug 2021 New trial record